1. Home
  2. KLAR vs INDV Comparison

KLAR vs INDV Comparison

Compare KLAR & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KLAR

Klarna Group plc Ordinary Shares

HOLD

Current Price

$17.62

Market Cap

5.5B

Sector

Finance

ML Signal

HOLD

Logo Indivior PLC

INDV

Indivior PLC

HOLD

Current Price

$38.09

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLAR
INDV
Founded
2005
N/A
Country
United Kingdom
United States
Employees
2831
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.4B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
KLAR
INDV
Price
$17.62
$38.09
Analyst Decision
Buy
Analyst Count
16
0
Target Price
$38.00
N/A
AVG Volume (30 Days)
5.3M
1.6M
Earning Date
05-14-2026
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
8100.00
EPS
N/A
0.69
Revenue
N/A
$1,239,000,000.00
Revenue This Year
$28.56
N/A
Revenue Next Year
$19.93
N/A
P/E Ratio
N/A
$55.77
Revenue Growth
N/A
4.29
52 Week Low
$12.06
$13.45
52 Week High
$47.48
$41.00

Technical Indicators

Market Signals
Indicator
KLAR
INDV
Relative Strength Index (RSI) 60.19 57.87
Support Level $12.77 $35.36
Resistance Level $18.55 $41.00
Average True Range (ATR) 0.91 1.35
MACD -0.10 0.10
Stochastic Oscillator 72.77 88.67

Price Performance

Historical Comparison
KLAR
INDV

About KLAR Klarna Group plc Ordinary Shares

Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.

About INDV Indivior PLC

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Share on Social Networks: